| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1009122397 |
| P356 | DOI | 10.1038/EYE.2012.284 |
| P932 | PMC publication ID | 3597885 |
| P698 | PubMed publication ID | 23412559 |
| P5875 | ResearchGate publication ID | 235629776 |
| P2093 | author name string | D H Verity | |
| G E Rose | |||
| P2860 | cites work | Selenium and the course of mild Graves' orbitopathy | Q28238021 |
| Protocol for the combined immunosuppression & radiotherapy in thyroid eye disease (CIRTED) trial: a multi-centre, double-masked, factorial randomised controlled trial | Q30481543 | ||
| Immunopathogenesis of thyroid eye disease: emerging paradigms | Q33789467 | ||
| Radiotherapy for thyroid-associated orbitopathy | Q33806019 | ||
| Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. | Q34010116 | ||
| HLA and tumour necrosis factor (TNF) polymorphisms in ocular Behçet's disease | Q34505321 | ||
| Orbital radiotherapy for Graves' ophthalmopathy | Q34599785 | ||
| Orbital decompression: current concepts | Q34827184 | ||
| Activated human T lymphocytes express cyclooxygenase-2 and produce proadipogenic prostaglandins that drive human orbital fibroblast differentiation to adipocytes | Q35222158 | ||
| The evolving role of selenium in the treatment of graves' disease and ophthalmopathy | Q35725329 | ||
| The pathophysiology of thyroid eye disease: implications for immunotherapy. | Q36439938 | ||
| Endoscopic orbital and optic nerve decompression | Q36498677 | ||
| B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding family | Q36897408 | ||
| The influence of selenium on immune responses | Q37045286 | ||
| Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy | Q37110191 | ||
| Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity | Q37829150 | ||
| Autoimmunity in Graves' ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors? | Q37890154 | ||
| Optimal management of Graves orbitopathy: a multidisciplinary approach. | Q37936059 | ||
| Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study | Q43705603 | ||
| Long-term safety of orbital radiotherapy for Graves' ophthalmopathy | Q44547490 | ||
| Relative overexpression of macrophage-derived cytokines in orbital adipose tissue from patients with graves' ophthalmopathy | Q44582494 | ||
| Methylprednisolone and hepatotoxicity in Graves' ophthalmopathy | Q44818300 | ||
| Measuring disease activity to predict therapeutic outcome in Graves' ophthalmopathy. | Q45237927 | ||
| Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy | Q46585048 | ||
| Transcaruncular orbital decompression: an alternate procedure for Graves ophthalmopathy with compressive optic neuropathy | Q46982986 | ||
| A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy. | Q53359335 | ||
| Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves' ophthalmopathy. | Q53758474 | ||
| Transnasal endoscopic orbital decompression and Graves' ophtalmopathy. | Q54044818 | ||
| Infliximab: A Novel Treatment for Sight-Threatening Thyroid Associated Ophthalmopathy | Q60207430 | ||
| Acute and Severe Liver Damage Associated with Intravenous Glucocorticoid Pulse Therapy in Patients with Graves' Ophthalmopathy | Q61054093 | ||
| Methimazole and propylthiouracil inhibit the oxygen free radical-induced expression of a 72 kilodalton heat shock protein in Graves' retroocular fibroblasts | Q68053807 | ||
| Azathioprine in the treatment of thyroid-associated ophthalmopathy | Q68713064 | ||
| Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy | Q69288448 | ||
| Pathogenesis of Graves' ophthalmopathy | Q70513409 | ||
| Low- versus high-dose radiotherapy for Graves' ophthalmopathy: a randomized, single blind trial | Q73351501 | ||
| Superoxide radical production stimulates retroocular fibroblast proliferation in Graves' ophthalmopathy | Q73618559 | ||
| Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease | Q74044567 | ||
| Oxygen free radicals in interleukin-1beta-induced glycosaminoglycan production by retro-ocular fibroblasts from normal subjects and Graves' ophthalmopathy patients | Q77351729 | ||
| Cigarette smoking and treatment outcomes in Graves ophthalmopathy | Q77458223 | ||
| Smoking and thyroid-associated ophthalmopathy: A novel explanation of the biological link | Q79259989 | ||
| Treatment of thyroid ophthalmopathy with corticoid analogues | Q79403964 | ||
| New-onset acute heart failure after intravenous glucocorticoid pulse therapy in a patient with Graves' ophthalmopathy | Q80193127 | ||
| Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves' ophthalmopathy | Q80689390 | ||
| Serum concentrations of interleukin (IL-)1alpha, 1beta, 6 and tumor necrosis factor (TNF-) alpha in patients with thyroid eye disease (TED) | Q80767500 | ||
| The effect of etanercept on Graves' ophthalmopathy: a pilot study | Q81024281 | ||
| New immunomodulators in the treatment of Graves' ophthalmopathy | Q81097416 | ||
| Monoclonal anti-TNFalpha antibody (infliximab) in the treatment of patient with thyroid associated ophthalmopathy | Q81300166 | ||
| Medial wall decompression for optic neuropathy but lateral wall decompression with fat removal for non vision-threatening indications | Q83296025 | ||
| Hypokalemic paralysis following administration of intravenous methylprednisolone in a patient with Graves' thyrotoxicosis and ophthalmopathy | Q83335036 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | eye disease | Q3041498 |
| P304 | page(s) | 308-19 | |
| P577 | publication date | 2013-03-01 | |
| P1433 | published in | Eye | Q10278937 |
| P1476 | title | Acute thyroid eye disease (TED): principles of medical and surgical management | |
| P478 | volume | 27 |
| Q51067652 | 99Tcm-octreotide scintigraphy and serum eye muscle antibodies in evaluation of active thyroid-associated ophthalmopathy. |
| Q47570741 | A case of concurrent silent sinus syndrome, thyroid eye disease, idiopathic orbital inflammatory syndrome, and dacryoadenitis |
| Q36305798 | An overview of thyroid eye disease |
| Q35364814 | Blood-aqueous barrier integrity in patients with Graves' ophthalmopathy (GO), before and after rehabilitative surgery. |
| Q38727516 | Chemodenervation of extraocular muscles with botulinum toxin in thyroid eye disease |
| Q42563364 | Comment on 'Acute thyroid eye disease (TED): principles of medical and surgical management'. |
| Q37283088 | Compressive Optic Neuropathy and Repeat Orbital Decompression: A Case Series |
| Q42433372 | Computer-Assisted Three-Dimensional Planning for Orbital Decompression |
| Q26800562 | Critical Appraisal on Orbital Decompression for Thyroid Eye Disease: A Systematic Review and Literature Search |
| Q91858998 | Current Understanding of the Progression and Management of Thyroid Associated Orbitopathy: A Systematic Review |
| Q53477841 | Enhanced-depth optical coherence tomography for imaging horizontal rectus muscles in Graves' orbitopathy. |
| Q92983927 | Influence of orbital morphology on proptosis reduction and ocular motility after decompression surgery in patients with Graves' orbitopathy |
| Q28293618 | Keratoglobus |
| Q92335694 | New insights into the pathogenesis and nonsurgical management of Graves orbitopathy |
| Q53101493 | Optical coherence tomography measurements in compressive optic neuropathy associated with dysthyroid orbitopathy. |
| Q90620071 | Position and size of the sphenoid door jamb in the lateral orbital wall for the orbital decompression |
| Q50967696 | Preoperative clinical features of reactivated of Graves' orbitopathy after orbital decompression. |
| Q90348519 | Reduced macular inner retinal thickness and microvascular density in the early stage of patients with dysthyroid optic neuropathy |
| Q42563368 | Response to Drs Litwin and Malhotra |
| Q35843225 | Results after En Bloc Lateral Wall Decompression Surgery with Orbital Fat Resection in 111 Patients with Graves' Orbitopathy |
| Q36349128 | Safety Profile and Effects of Pulsed Methylprednisolone on Vital Signs in Thyroid Eye Disease |
| Q38888403 | Socioeconomic Disparities in the Presentation and Treatment of Graves' Disease and Thyroid Eye Disease |
| Q45892156 | Survey of common practices among oculofacial surgeons in the Asia-Pacific region: Graves' orbitopathy |
| Q26749195 | THERAPY OF ENDOCRINE DISEASE: Endocrine dilemma: management of Graves' orbitopathy |
| Q90695307 | Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis |
| Q91789199 | Thyroid Eye Disease: How A Novel Therapy May Change The Treatment Paradigm |
| Q38971992 | Thyroid eye disease: a review |
| Q53127050 | [Graves' ophthalmopathy]. |
| Q54325672 | [Orbital decompression : Indications, technique, results]. |
| Q48913225 | [Update on endocrine orbitopathy]. |
Search more.